Tag Archives: Merrimack Pharmaceuticals

June, 2018

25 June
Merrimack Halts Development of its Investigational Pancreatic Cancer Drug After Failing to Meet Endpoints in Phase 2 Trial

CAMBRIDGE, Mass., June 25, 2018 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced top-line results from the CARRIE study, a randomized Phase 2 trial evaluating the addition of MM-141 (istiratumab) to standard-of-care treatment in patients with previously untreated metastatic pancreatic cancer and high serum levels …
Share

6 July
Merrimack’s NSCLC Drug Receives Fast Track Designation from the FDA

CAMBRIDGE, Mass., July 6, 2016 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted seribantumab, also known as MM-121, Fast Track designation for development in patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has …
Share

30 June
Merrimack’s Pancreatic Cancer Regimen Maintains QOL While Improving Overall Survival in Clinical Trial

CAMBRIDGE, Mass., June 30, 2016 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced a newly presented analysis of the Phase 3 NAPOLI-1 data shows patients treated with ONIVYDE® (irinotecan liposome injection), also known as “nal-IRI,” in combination with fluorouracil (5-FU) and leucovorin, maintain similar baseline quality of life at …
Share

22 October
Merrimack Pharmaceuticals’ Pancreatic Cancer Drug Wins Expedited FDA Approval

MANHATTAN BEACH, Calif., Oct. 22, 2015 /PRNewswire-USNewswire/ — Today, The U.S. Food and Drug Administration (FDA) approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim …
Share

4 May
Baxter and Merrimack File for Approval of its Pancreatic Cancer Drug in Europe

Today, Baxter Bioscience and Merrimack Pharmaceuticals announced that the companies have submitted a marketing authorization application (MAA) for approval of its investigational treatment for patients with pancreatic cancer in Europe. The companies said that they have submitted an application to the European Medicines Agency (EMA) for approval of MM-398, also …
Share